| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NOTC1, NOTCH1, TAN1, hN1, neurogenic locus notch homolog protein 1, neurogenic locus notch homolog protein 1 precursor,;Notch 1 |
| WB Predicted band size | Calculated MW: 273 kDa ; Observed MW: 125 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human Notch 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4篇关于Notch1抗体的代表性文献，按文献名称、作者和摘要内容简要整理：
---
1. **文献名称**：*Notch1 mutations are critical for leukemic transformation in T-cell acute lymphoblastic leukemia*
**作者**：Jon C. Aster, Warren S. Pear, et al.
**摘要**：通过Notch1特异性抗体进行Western blot和免疫组化分析，揭示了Notch1基因突变在T细胞急性淋巴细胞白血病(T-ALL)中的致癌作用，证明突变导致Notch1胞内结构域(NICD)的持续激活。
2. **文献名称**：*Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis*
**作者**：R. Benedito, M. Hellström
**摘要**：利用Notch1抗体进行免疫荧光染色，研究Notch1-Dll4信号在血管生成中的调控作用，发现其通过抑制内皮细胞尖端化影响血管分支模式。
3. **文献名称**：*Notch1 regulates the fate of cardiac progenitor cells by repressing Sox2*
**作者**：T. J. Nelson, A. Terzic, et al.
**摘要**：通过Notch1抗体检测心脏祖细胞中Notch1的表达，揭示Notch1通过抑制Sox2转录因子调控细胞分化方向，影响心脏发育与再生。
4. **文献名称**：*Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts*
**作者**：I. D. Lewis, D. W. Scott, et al.
**摘要**：开发了一种针对Notch1胞外结构域的单克隆抗体，在T-ALL异种移植模型中验证其抑制肿瘤生长的效果，为靶向Notch1的癌症治疗提供实验依据。
---
这些文献覆盖了Notch1抗体在基础研究(信号机制、发育调控)和临床转化(癌症靶向治疗)中的关键应用。如需具体DOI或发表年份，可进一步补充。
The Notch1 antibody is a crucial tool for studying the Notch signaling pathway, a highly conserved system regulating cell differentiation, proliferation, and apoptosis. Notch1. a transmembrane receptor, is activated upon binding to ligands (e.g., Delta-like or Jagged proteins), triggering proteolytic cleavage and releasing its intracellular domain (NICD). This domain translocates to the nucleus to modulate gene expression. Dysregulation of Notch1 is implicated in cancers, cardiovascular diseases, and developmental disorders. In oncology, Notch1 exhibits dual roles: it acts as an oncogene in T-cell acute lymphoblastic leukemia (T-ALL) and promotes tumor growth in breast cancer, while functioning as a tumor suppressor in squamous cell carcinomas.
Notch1 antibodies are widely used in research to detect protein expression, localization, and activation status via techniques like Western blot, immunohistochemistry (IHC), and flow cytometry. They help elucidate Notch1's role in disease mechanisms and therapeutic targeting. Commercial antibodies target specific epitopes, such as the extracellular domain (ECD) or the cleaved NICD, with validation often involving knockout cell lines or tissue controls. Recent studies also explore Notch1 antibodies as potential diagnostic biomarkers or therapeutic agents, particularly in blocking aberrant signaling in cancers. However, challenges remain in ensuring antibody specificity due to structural similarities among Notch family members (Notch1-4). Ongoing research continues to refine antibody applications, emphasizing their value in both basic science and clinical translation.
×
